uniQure (NASDAQ:QURE) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen upgraded shares of uniQure (NASDAQ:QURE - Free Report) from a sell rating to a hold rating in a research note released on Saturday.

A number of other equities analysts have also weighed in on QURE. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Chardan Capital reiterated a "buy" rating and set a $38.00 target price on shares of uniQure in a research report on Monday, May 12th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a research report on Monday, April 21st. Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. Finally, Wells Fargo & Company lowered their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Price Performance

Shares of uniQure stock traded down $0.14 during midday trading on Friday, hitting $14.90. 960,595 shares of the company traded hands, compared to its average volume of 1,898,572. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a market cap of $816.16 million, a price-to-earnings ratio of -3.00 and a beta of 0.10. The firm's fifty day moving average price is $12.53 and its 200-day moving average price is $12.81.

uniQure (NASDAQ:QURE - Get Free Report) last released its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. As a group, sell-side analysts forecast that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other uniQure news, CFO Christian Klemt sold 10,438 shares of uniQure stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the transaction, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. The trade was a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the transaction, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. This trade represents a 4.17% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,129 shares of company stock worth $412,927. 4.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On uniQure

Hedge funds have recently modified their holdings of the stock. Invesco Ltd. increased its holdings in shares of uniQure by 453.2% during the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after acquiring an additional 502,684 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in uniQure in the fourth quarter valued at approximately $320,000. Palumbo Wealth Management LLC purchased a new stake in uniQure in the fourth quarter valued at approximately $437,000. Raymond James Financial Inc. purchased a new stake in uniQure in the fourth quarter valued at approximately $1,951,000. Finally, Northern Trust Corp boosted its position in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after buying an additional 1,923 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.